120 related articles for article (PubMed ID: 17139156)
21. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.
Fujieda M; Yamazaki H; Saito T; Kiyotani K; Gyamfi MA; Sakurai M; Dosaka-Akita H; Sawamura Y; Yokota J; Kunitoh H; Kamataki T
Carcinogenesis; 2004 Dec; 25(12):2451-8. PubMed ID: 15308589
[TBL] [Abstract][Full Text] [Related]
22. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo.
Sellers EM; Ramamoorthy Y; Zeman MV; Djordjevic MV; Tyndale RF
Nicotine Tob Res; 2003 Dec; 5(6):891-9. PubMed ID: 14668073
[TBL] [Abstract][Full Text] [Related]
23. Stereospecific deuterium substitution attenuates the tumorigenicity and metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).
Jalas JR; McIntee EJ; Kenney PM; Upadhyaya P; Peterson LA; Hecht SS
Chem Res Toxicol; 2003 Jun; 16(6):794-806. PubMed ID: 12807363
[TBL] [Abstract][Full Text] [Related]
24. CYP2A6 gene deletion reduces susceptibility to lung cancer.
Miyamoto M; Umetsu Y; Dosaka-Akita H; Sawamura Y; Yokota J; Kunitoh H; Nemoto N; Sato K; Ariyoshi N; Kamataki T
Biochem Biophys Res Commun; 1999 Aug; 261(3):658-60. PubMed ID: 10441482
[TBL] [Abstract][Full Text] [Related]
25. Characterization of cytochrome P450 2A4 and 2A5-catalyzed 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism.
Felicia ND; Rekha GK; Murphy SE
Arch Biochem Biophys; 2000 Dec; 384(2):418-24. PubMed ID: 11368333
[TBL] [Abstract][Full Text] [Related]
26. Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase.
Fujita K; Kamataki T
Environ Mol Mutagen; 2001; 38(4):339-46. PubMed ID: 11774366
[TBL] [Abstract][Full Text] [Related]
27. Analysis of CYP2A contributions to metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human peripheral lung microsomes.
Brown PJ; Bedard LL; Reid KR; Petsikas D; Massey TE
Drug Metab Dispos; 2007 Nov; 35(11):2086-94. PubMed ID: 17717079
[TBL] [Abstract][Full Text] [Related]
28. Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen.
He XY; Shen J; Ding X; Lu AY; Hong JY
Drug Metab Dispos; 2004 Dec; 32(12):1516-21. PubMed ID: 15333516
[TBL] [Abstract][Full Text] [Related]
29. CYP2A6 polymorphisms and risk for tobacco-related cancers.
Rossini A; de Almeida Simão T; Albano RM; Pinto LF
Pharmacogenomics; 2008 Nov; 9(11):1737-52. PubMed ID: 19018727
[TBL] [Abstract][Full Text] [Related]
30. Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in smokers.
von Weymarn LB; Chun JA; Hollenberg PF
Carcinogenesis; 2006 Apr; 27(4):782-90. PubMed ID: 16364922
[TBL] [Abstract][Full Text] [Related]
31. Benzylmorpholine analogs as selective inhibitors of lung cytochrome P450 2A13 for the chemoprevention of lung cancer in tobacco users.
Blake LC; Roy A; Neul D; Schoenen FJ; Aubé J; Scott EE
Pharm Res; 2013 Sep; 30(9):2290-302. PubMed ID: 23756756
[TBL] [Abstract][Full Text] [Related]
32. Effects of cytochrome P450 (CYP) 2A6 gene deletion and CYP2E1 genotypes on gastric adenocarcinoma.
Tsukino H; Kuroda Y; Qiu D; Nakao H; Imai H; Katoh T
Int J Cancer; 2002 Aug; 100(4):425-8. PubMed ID: 12115524
[TBL] [Abstract][Full Text] [Related]
33. Polymorphisms of CYP2A6 and its practical consequences.
Raunio H; Rautio A; Gullstén H; Pelkonen O
Br J Clin Pharmacol; 2001 Oct; 52(4):357-63. PubMed ID: 11678779
[TBL] [Abstract][Full Text] [Related]
34. Association between CYP2A6 genetic polymorphisms and lung cancer: a meta-analysis of case-control studies.
Liu T; Xie CB; Ma WJ; Chen WQ
Environ Mol Mutagen; 2013 Mar; 54(2):133-40. PubMed ID: 23203414
[TBL] [Abstract][Full Text] [Related]
35. CYP2A6 polymorphism, nicotine, and environmental nitrosamines.
Idle JR
Lancet; 1999 Jun; 353(9169):2073. PubMed ID: 10376647
[No Abstract] [Full Text] [Related]
36. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Su T; Bao Z; Zhang QY; Smith TJ; Hong JY; Ding X
Cancer Res; 2000 Sep; 60(18):5074-9. PubMed ID: 11016631
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of stereospecifically deuterated 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) iastereomers and metabolism by A/J mouse lung microsomes and cytochrome p450 2A5.
Jalas JR; Hecht SS
Chem Res Toxicol; 2003 Jun; 16(6):782-93. PubMed ID: 12807362
[TBL] [Abstract][Full Text] [Related]
38. Chemopreventive effects of fermented brown rice and rice bran against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in female A/J mice.
Phutthaphadoong S; Yamada Y; Hirata A; Tomita H; Taguchi A; Hara A; Limtrakul PN; Iwasaki T; Kobayashi H; Mori H
Oncol Rep; 2009 Feb; 21(2):321-7. PubMed ID: 19148502
[TBL] [Abstract][Full Text] [Related]
39. N-nitrosodiethylamine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced morphological transformation of C3H/10T1/2CL8 cells expressing human cytochrome P450 2A6.
Nesnow S; Beck S; Rosenblum S; Lasley J; Tiano HF; Hosokawa M; Crespi CL; Langenbach R
Mutat Res; 1994 Jul; 324(3):93-102. PubMed ID: 8022436
[TBL] [Abstract][Full Text] [Related]
40. Exposure and Metabolic Activation Biomarkers of Carcinogenic Tobacco-Specific Nitrosamines.
Hecht SS; Stepanov I; Carmella SG
Acc Chem Res; 2016 Jan; 49(1):106-14. PubMed ID: 26678241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
